- Home
- BRTX vs SABS Comparison
BRTX vs SABS Comparison
Compare BRTX & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- SABS
- Stock Information
- Founded
- BRTX 1997
- SABS 2014
- Country
- BRTX United States
- SABS United States
- Employees
- BRTX N/A
- SABS N/A
- Industry
- BRTX Managed Health Care
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- BRTX Health Care
- SABS Health Care
- Exchange
- BRTX Nasdaq
- SABS Nasdaq
- Market Cap
- BRTX 15.9M
- SABS 19.0M
- IPO Year
- BRTX N/A
- SABS N/A
- Fundamental
- Price
- BRTX $1.80
- SABS $1.82
- Analyst Decision
- BRTX Strong Buy
- SABS Strong Buy
- Analyst Count
- BRTX 1
- SABS 5
- Target Price
- BRTX $18.00
- SABS $12.40
- AVG Volume (30 Days)
- BRTX 812.7K
- SABS 246.2K
- Earning Date
- BRTX 03-28-2025
- SABS 03-28-2025
- Dividend Yield
- BRTX N/A
- SABS N/A
- EPS Growth
- BRTX N/A
- SABS N/A
- EPS
- BRTX N/A
- SABS N/A
- Revenue
- BRTX $377,000.00
- SABS $1,512,723.00
- Revenue This Year
- BRTX $482.76
- SABS N/A
- Revenue Next Year
- BRTX $212.24
- SABS N/A
- P/E Ratio
- BRTX N/A
- SABS N/A
- Revenue Growth
- BRTX 189.55
- SABS N/A
- 52 Week Low
- BRTX $1.03
- SABS $1.60
- 52 Week High
- BRTX $2.55
- SABS $6.30
- Technical
- Relative Strength Index (RSI)
- BRTX 37.55
- SABS 36.28
- Support Level
- BRTX $2.26
- SABS $2.00
- Resistance Level
- BRTX $2.38
- SABS $2.15
- Average True Range (ATR)
- BRTX 0.22
- SABS 0.20
- MACD
- BRTX -0.09
- SABS 0.03
- Stochastic Oscillator
- BRTX 7.98
- SABS 30.99
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.